A potential role of YC-I on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models

Shiow Lin Pan, Jin Hwa Guh, Chieh Yu Peng, Ya Ling Chang, Fong Chi Cheng, Jau Hsiang Chang, Sheng Chu Kuo, Fang Yu Lee, Che Ming Teng

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

To evaluate the anti-sepsis potential of YC-1, we have examined the effect of YC-1 on the regulation of cytokine production in human leukocytes and endotoxemic mice. The data demonstrated that YC-1 showed a preferential inhibition on proinflammatory cytokine production without inhibition of cell growth or induction of cytotoxicity in human leukocytes. On the other hand, in the septic mouse model, treatment with an intraperitoneal application of LPS caused a cumulative death within 27 hours. The post-treatment administration of YC-1 significantly increased the survival rate in endotoxemic mice. Furthermore, several mediators were detected and the data showed that YC-1 profoundly blocked LPS-induced NO as well as TNF-α production, and prevented lung damage by histological examination. Samples from the animal model showed that LPS-induced NF-κB/DNA binding activity and consequent up-regulation of iNOS expression in tissues were abolished by post-administration of YC-1. Furthermore, YC-1, by itself, did not modify cGMP content while significantly inhibit LPS-induced cGMP formation, suggesting that YC-1-mediated effect was not through a cGMP-elevating pathway.Taken together, it is evident that the post-treatment administration of YC-1 after LPS application significantly inhibits NF-κB activation, iNOS expression, NO over-production, and cytokine release reaction resulting in an improved survival rate in endotoxemic mice. It is suggested that YC-1 may be a potential agent for the therapeutic treatment of sepsis.

Original languageEnglish
Pages (from-to)940-948
Number of pages9
JournalThrombosis and Haemostasis
Volume93
Issue number5
DOIs
Publication statusPublished - May 2005
Externally publishedYes

Fingerprint

Mononuclear Leukocytes
Cytokines
Sepsis
Leukocytes
Up-Regulation
Animal Models
Lung
DNA
Growth
Therapeutics

Keywords

  • Lipopolysaccharide
  • Nuclear factor-κB
  • YC-I

ASJC Scopus subject areas

  • Hematology

Cite this

A potential role of YC-I on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. / Pan, Shiow Lin; Guh, Jin Hwa; Peng, Chieh Yu; Chang, Ya Ling; Cheng, Fong Chi; Chang, Jau Hsiang; Kuo, Sheng Chu; Lee, Fang Yu; Teng, Che Ming.

In: Thrombosis and Haemostasis, Vol. 93, No. 5, 05.2005, p. 940-948.

Research output: Contribution to journalArticle

Pan, Shiow Lin ; Guh, Jin Hwa ; Peng, Chieh Yu ; Chang, Ya Ling ; Cheng, Fong Chi ; Chang, Jau Hsiang ; Kuo, Sheng Chu ; Lee, Fang Yu ; Teng, Che Ming. / A potential role of YC-I on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. In: Thrombosis and Haemostasis. 2005 ; Vol. 93, No. 5. pp. 940-948.
@article{199304fb3f3741ffabe7ea0ec8b64fac,
title = "A potential role of YC-I on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models",
abstract = "To evaluate the anti-sepsis potential of YC-1, we have examined the effect of YC-1 on the regulation of cytokine production in human leukocytes and endotoxemic mice. The data demonstrated that YC-1 showed a preferential inhibition on proinflammatory cytokine production without inhibition of cell growth or induction of cytotoxicity in human leukocytes. On the other hand, in the septic mouse model, treatment with an intraperitoneal application of LPS caused a cumulative death within 27 hours. The post-treatment administration of YC-1 significantly increased the survival rate in endotoxemic mice. Furthermore, several mediators were detected and the data showed that YC-1 profoundly blocked LPS-induced NO as well as TNF-α production, and prevented lung damage by histological examination. Samples from the animal model showed that LPS-induced NF-κB/DNA binding activity and consequent up-regulation of iNOS expression in tissues were abolished by post-administration of YC-1. Furthermore, YC-1, by itself, did not modify cGMP content while significantly inhibit LPS-induced cGMP formation, suggesting that YC-1-mediated effect was not through a cGMP-elevating pathway.Taken together, it is evident that the post-treatment administration of YC-1 after LPS application significantly inhibits NF-κB activation, iNOS expression, NO over-production, and cytokine release reaction resulting in an improved survival rate in endotoxemic mice. It is suggested that YC-1 may be a potential agent for the therapeutic treatment of sepsis.",
keywords = "Lipopolysaccharide, Nuclear factor-κB, YC-I",
author = "Pan, {Shiow Lin} and Guh, {Jin Hwa} and Peng, {Chieh Yu} and Chang, {Ya Ling} and Cheng, {Fong Chi} and Chang, {Jau Hsiang} and Kuo, {Sheng Chu} and Lee, {Fang Yu} and Teng, {Che Ming}",
year = "2005",
month = "5",
doi = "10.1160/TH04-03-0195",
language = "English",
volume = "93",
pages = "940--948",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "5",

}

TY - JOUR

T1 - A potential role of YC-I on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models

AU - Pan, Shiow Lin

AU - Guh, Jin Hwa

AU - Peng, Chieh Yu

AU - Chang, Ya Ling

AU - Cheng, Fong Chi

AU - Chang, Jau Hsiang

AU - Kuo, Sheng Chu

AU - Lee, Fang Yu

AU - Teng, Che Ming

PY - 2005/5

Y1 - 2005/5

N2 - To evaluate the anti-sepsis potential of YC-1, we have examined the effect of YC-1 on the regulation of cytokine production in human leukocytes and endotoxemic mice. The data demonstrated that YC-1 showed a preferential inhibition on proinflammatory cytokine production without inhibition of cell growth or induction of cytotoxicity in human leukocytes. On the other hand, in the septic mouse model, treatment with an intraperitoneal application of LPS caused a cumulative death within 27 hours. The post-treatment administration of YC-1 significantly increased the survival rate in endotoxemic mice. Furthermore, several mediators were detected and the data showed that YC-1 profoundly blocked LPS-induced NO as well as TNF-α production, and prevented lung damage by histological examination. Samples from the animal model showed that LPS-induced NF-κB/DNA binding activity and consequent up-regulation of iNOS expression in tissues were abolished by post-administration of YC-1. Furthermore, YC-1, by itself, did not modify cGMP content while significantly inhibit LPS-induced cGMP formation, suggesting that YC-1-mediated effect was not through a cGMP-elevating pathway.Taken together, it is evident that the post-treatment administration of YC-1 after LPS application significantly inhibits NF-κB activation, iNOS expression, NO over-production, and cytokine release reaction resulting in an improved survival rate in endotoxemic mice. It is suggested that YC-1 may be a potential agent for the therapeutic treatment of sepsis.

AB - To evaluate the anti-sepsis potential of YC-1, we have examined the effect of YC-1 on the regulation of cytokine production in human leukocytes and endotoxemic mice. The data demonstrated that YC-1 showed a preferential inhibition on proinflammatory cytokine production without inhibition of cell growth or induction of cytotoxicity in human leukocytes. On the other hand, in the septic mouse model, treatment with an intraperitoneal application of LPS caused a cumulative death within 27 hours. The post-treatment administration of YC-1 significantly increased the survival rate in endotoxemic mice. Furthermore, several mediators were detected and the data showed that YC-1 profoundly blocked LPS-induced NO as well as TNF-α production, and prevented lung damage by histological examination. Samples from the animal model showed that LPS-induced NF-κB/DNA binding activity and consequent up-regulation of iNOS expression in tissues were abolished by post-administration of YC-1. Furthermore, YC-1, by itself, did not modify cGMP content while significantly inhibit LPS-induced cGMP formation, suggesting that YC-1-mediated effect was not through a cGMP-elevating pathway.Taken together, it is evident that the post-treatment administration of YC-1 after LPS application significantly inhibits NF-κB activation, iNOS expression, NO over-production, and cytokine release reaction resulting in an improved survival rate in endotoxemic mice. It is suggested that YC-1 may be a potential agent for the therapeutic treatment of sepsis.

KW - Lipopolysaccharide

KW - Nuclear factor-κB

KW - YC-I

UR - http://www.scopus.com/inward/record.url?scp=18844366701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844366701&partnerID=8YFLogxK

U2 - 10.1160/TH04-03-0195

DO - 10.1160/TH04-03-0195

M3 - Article

VL - 93

SP - 940

EP - 948

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 5

ER -